Source 1primary paper2025MED
Toolkit/IMP305
IMP305
Also known as: ultrasound-activated IMP305, ultrasound-sensitive liposome
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
IMP305 was developed as an ultrasound-sensitive liposome for tumor-localized drug release. In particular, IMP305 is dominantly capable of release by ultrasound-mediated cavitation.
Usefulness & Problems
No literature-backed usefulness or problem-fit explainer has been materialized for this record yet.
Published Workflows
Objective: Develop and evaluate an ultrasound-sensitive liposomal exatecan platform for tumor-localized drug release in pancreatic ductal adenocarcinoma.
Why it works: The abstract states that IMP305 combines tumor-specific drug delivery with cavitation-induced loosening of PDAC stromal architecture, enabling more efficient intratumoral drug release.
ultrasound-mediated cavitationcavitation-induced loosening of stromal architecturetriggered release of encapsulated exatecanliposomal encapsulationfocused ultrasound activationxenograft efficacy testing
Stages
- 1.Triggered release characterization(functional_characterization)
This stage establishes that IMP305 can be structurally disrupted by cavitation and can release encapsulated exatecan before therapeutic testing.
Selection: Extent of cavitation-triggered structural disruption and exatecan release from IMP305.
- 2.In vivo efficacy and tolerability evaluation(in_vivo_validation)
This stage tests whether the formulation's triggered-release behavior translates into improved tolerated dose and antitumor efficacy in vivo.
Selection: Maximal tolerated dose and antitumor benefit in PANC-1 xenograft mice, including focused ultrasound combination.
Steps
- 1.Measure cavitation-triggered structural disruption of IMP305engineered formulation being characterized
Assess whether ultrasound-mediated cavitation disrupts the liposomal structure.
The abstract presents structural disruption as the mechanistic basis for subsequent exatecan release.
- 2.Quantify exatecan release after cavitation-triggered disruptionengineered formulation being characterized
Determine how much encapsulated exatecan is released after cavitation-triggered disruption.
The abstract explicitly links structural disruption to robust release of encapsulated exatecan.
- 3.Evaluate tolerated dose and antitumor activity in PANC-1 xenograft micetherapeutic formulation under test
Test whether IMP305 improves tolerated dose and antitumor efficacy in vivo.
After showing triggered release behavior, the study tests whether the formulation improves therapeutic performance in the disease model.
- 4.Combine IMP305 with focused ultrasound to test maximal therapeutic benefittherapeutic formulation activated by ultrasound
Determine whether focused ultrasound further improves therapeutic outcome beyond IMP305 alone.
The abstract identifies focused ultrasound combination as producing the most pronounced therapeutic benefit, making it a downstream activation condition after establishing baseline in vivo activity.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A delivery strategy grouped with the mechanism branch because it determines how a system is instantiated and deployed in context.
Mechanisms
cavitation-triggered structural disruptiontriggered payload releaseultrasound-mediated cavitationTechniques
Structural CharacterizationTarget processes
recombinationInput: Chemical
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Observations
successMouseapplication demomousePANC-1 xenograft
Inferred from claim c5 during normalization. Ultrasound-activated IMP305 enhances intratumoral accumulation and release of exatecan while mitigating systemic toxicity. Derived from claim c5. Quoted text: these findings demonstrate that ultrasound-activated IMP305 significantly enhances intratumoral accumulation and release of exatecan, resulting in superior tumor suppression while mitigating systemic toxicity.
Source:
successMousetherapeutic usemousePANC-1 xenograft
Inferred from claim c4 during normalization. IMP305 showed superior antitumor activity in PANC-1 xenograft models, with the strongest benefit when combined with focused ultrasound. Derived from claim c4. Quoted text: IMP305 exhibited a maximal tolerance dose approximately four times higher than that of free exatecan and demonstrated markedly superior antitumor ability. Especially, IMP305 combined with focused ultrasound achieved the most pronounced therapeutic benefit, demonstrating a 49.17 ± 9.00% reduction in tumor volume at day 48 and an 80% survival rate at day 60.
Source:
survival rate(80%)tumor volume reduction(49.17 ± 9.00%)
Supporting Sources
Ranked Claims
Ultrasound-activated IMP305 enhances intratumoral accumulation and release of exatecan while mitigating systemic toxicity.
these findings demonstrate that ultrasound-activated IMP305 significantly enhances intratumoral accumulation and release of exatecan, resulting in superior tumor suppression while mitigating systemic toxicity.
IMP305 is an ultrasound-sensitive liposome that is dominantly capable of drug release by ultrasound-mediated cavitation.
IMP305 was developed as an ultrasound-sensitive liposome for tumor-localized drug release. In particular, IMP305 is dominantly capable of release by ultrasound-mediated cavitation.
Encapsulation of exatecan into IMP305 increased the maximal tolerated dose relative to free exatecan.
The maximal tolerance dose of exatecan was increased by encapsulation into IMP305. In PANC-1 xenograft models, IMP305 exhibited a maximal tolerance dose approximately four times higher than that of free exatecan
maximal tolerated dose increase versus free exatecan 4 fold
Cavitation-triggered structural disruption of IMP305 produced robust release of encapsulated exatecan.
Cavitation-triggered structural disruption of IMP305 was 84.68 ± 6.21%, which resulted in a robust release of approximately 84.4 ± 1.95% of the encapsulated exatecan.
encapsulated exatecan release approximately 84.4 ± 1.95%structural disruption 84.68 ± 6.21%
IMP305 showed superior antitumor activity in PANC-1 xenograft models, with the strongest benefit when combined with focused ultrasound.
IMP305 exhibited a maximal tolerance dose approximately four times higher than that of free exatecan and demonstrated markedly superior antitumor ability. Especially, IMP305 combined with focused ultrasound achieved the most pronounced therapeutic benefit, demonstrating a 49.17 ± 9.00% reduction in tumor volume at day 48 and an 80% survival rate at day 60.
survival rate 80%tumor volume reduction 49.17 ± 9.00%
Approval Evidence
1 source5 linked approval claimsfirst-pass slug imp305
IMP305 was developed as an ultrasound-sensitive liposome for tumor-localized drug release. In particular, IMP305 is dominantly capable of release by ultrasound-mediated cavitation.
Source:
delivery outcomesupports
Ultrasound-activated IMP305 enhances intratumoral accumulation and release of exatecan while mitigating systemic toxicity.
these findings demonstrate that ultrasound-activated IMP305 significantly enhances intratumoral accumulation and release of exatecan, resulting in superior tumor suppression while mitigating systemic toxicity.
Source:
mechanismsupports
IMP305 is an ultrasound-sensitive liposome that is dominantly capable of drug release by ultrasound-mediated cavitation.
IMP305 was developed as an ultrasound-sensitive liposome for tumor-localized drug release. In particular, IMP305 is dominantly capable of release by ultrasound-mediated cavitation.
Source:
performancesupports
Encapsulation of exatecan into IMP305 increased the maximal tolerated dose relative to free exatecan.
The maximal tolerance dose of exatecan was increased by encapsulation into IMP305. In PANC-1 xenograft models, IMP305 exhibited a maximal tolerance dose approximately four times higher than that of free exatecan
Source:
release metricsupports
Cavitation-triggered structural disruption of IMP305 produced robust release of encapsulated exatecan.
Cavitation-triggered structural disruption of IMP305 was 84.68 ± 6.21%, which resulted in a robust release of approximately 84.4 ± 1.95% of the encapsulated exatecan.
Source:
therapeutic efficacysupports
IMP305 showed superior antitumor activity in PANC-1 xenograft models, with the strongest benefit when combined with focused ultrasound.
IMP305 exhibited a maximal tolerance dose approximately four times higher than that of free exatecan and demonstrated markedly superior antitumor ability. Especially, IMP305 combined with focused ultrasound achieved the most pronounced therapeutic benefit, demonstrating a 49.17 ± 9.00% reduction in tumor volume at day 48 and an 80% survival rate at day 60.
Source:
Comparisons
No literature-backed comparison notes have been materialized for this record yet.
Ranked Citations
- 1.